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Abstract
Gut microbes symbiotically colonize the gastrointestinal (GI) tract, interacting
with each other and their host to maintain GI tract homeostasis. Recent reports
have shown that gut microbes help protect the gut from colonization by
pathogenic microbes. Here, we report that commensal microbes prevent
colonization of the GI tract by the pathogenic fungus, Candida albicans. Wild‐
type specific pathogen‐free (SPF) mice are resistant to C. albicans colonization
of the GI tract. However, administering certain antibiotics to SPF mice enables
C. albicans colonization. Quantitative kinetics of commensal bacteria are
inversely correlated with the number of C. albicans in the gut. Here, we provide
further evidence that transplantation of fecal microbiota is effective in
preventing Candida colonization of the GI tract. These data demonstrate the
importance of commensal bacteria as a barrier for the GI tract surface and
highlight the potential clinical applications of commensal bacteria in preventing
pathogenic fungal infections.
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1 | INTRODUCTION
Many microbes, including bacteria, fungi, viruses, and
parasites, symbiotically colonize the GI tract.1 These
microbes interact dynamically with each other and their
host to maintain homeostasis. Dysbiosis, a disruption in
the homeostasis of the gut microbiota, is postulated to
cause various host diseases, including inflammatory bowel
diseases, metabolic syndrome, cancer and infection.1,2 Gut
microbes play important roles in resisting colonization and
protecting the host from infection by pathogenic mi-
crobes.2,3 For example, commensal bacteria prevent
infection by enteropathogenic bacteria such as Listeria
monocytogenes, Citrobacter rodentium, Salmonella typhi-
murium, vancomycin‐resistant Enterococcus and Clostri-
dium difficile.3–7 On the basis of the commensal bacterial
characteristics that protect the host from pathogen
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Abbreviations: FMT, fecal microbiota transplantation; GI, gastro-
intestinal; ITS, internal transcribed spacer; PDA, potato dextrose agar;
SFB, segmented filamentous bacteria; SPF, specific pathogen‐free.
colonization, FMT, a therapeutic strategy using commen-
sal bacteria, has been developed and implemented and
found to eradicate C. Difficile infection in humans.8
Recent studies have shown that fungi are also major
components of the human microbiota.9,10 In healthy
people, fungi reside in the oral cavity and GI and
urogenital tracts; however, these fungi infect immuno-
compromised hosts, including patients in intensive
care units, those infected with HIV, patients receiving
anticancer drugs and antibiotics, and patients who
have undergone allograft transplantation.11 In addition
to superficially infecting the skin or mucous mem-
branes, fungi invade the bloodstream and disseminate
to internal organs, infecting deep tissues and causing
invasive candidiasis, a serious infectious disease.11
Candida albicans is highly prevalent and constant in
human feces, suggesting that it is a commensal fungus
in the GI tract.9,10 However, C. albicans colonization of
the GI tract is thought to trigger invasive candidiasis.11
Thus, the mechanism by which C. albicans steadily
colonizes the GI tract requires identification. Previous
studies have shown that multiple antibiotics affect
colonization of the GI tract by C. albicans.12,13
Although these reports suggest that commensal bacter-
ia resist C. albicans colonization in the GI tract,
detailed mechanisms and bacterial species responsible
for this resistance to colonization have yet to be
established.
Antifungal drug‐resistant Candida has recently emerged
as a public health problem that can be life‐threatening to
humans.14 Thus, in addition to conventional antifungal
drugs, alternative strategies are needed to prevent Candida
infections. Here, we investigated the role of commensal
bacteria in regulating C. albicans colonization in the GI
tract. We used novel sequencing and PCR approaches to
investigate the microbiota present during treatment with
various antibiotics. We also examined the potential of
commensal bacteria as therapeutic targets for C. albicans
infections.
2 | MATERIALS AND METHODS
2.1 | Mice
Six‐ to ten‐week‐old C57BL/6 and BALB/c SPF mice were
purchased from CLEA Japan (Tokyo, Japan). All animals
were maintained with a gamma ray‐sterilized diet, sterile
water and autoclaved wood chip bedding in the experi-
mental animal facility at the Medical Mycology Research
Center. The Animal Care and Use Committee of the
Chiba University approved the experiments.
2.2 | Antibiotic treatment
Mice were given the following broad‐spectrum antibiotics in
their drinking water: ampicillin (1 g/L; Nacalai Tesque,
Kyoto, Japan), vancomycin (0.5 g/L; Shionogi, Osaka, Japan),
neomycin (1 g/L; Nacalai Tesque), metronidazole (1 g/L;
Nacalai Tesque), penicillin (1.5 g/L; Meiji Seika Pharma,
Tokyo, Japan), streptomycin (2 g/L; Nacalai Tesque), genta-
mycin (0.1 g/L; Nacalai Tesque) and colistin (1 g/L; MP
Biomedicals, Santa Ana, CA, USA).15–17 These antibiotic
treatments were continued throughout the experiments. For
the quantitative kinetic experiments, mice were orally
administered 0.5mg ampicillin 1 d before injection with
C. albicans.
2.3 | Isolation of fecal bacterial DNA
Fecal bacterial DNA was isolated as previously reported
with modifications.18 Mouse feces were collected, weighed,
added to tubes containing glass beads, and suspended in
500 μL of DNA extraction buffer (200mM Tris‐HCl, 20mM
EDTA, 200mM NaCl; pH8.0), 210 μL of 10% SDS, and 500
μL of buffer‐saturated phenol. The mixtures were agitated
vigorously for 60 s using a FastPrep‐24 5G homogenizer
(MP Biomedicals). After centrifugation at 14,000 rpm for
5min, 400 μL of supernatant were collected into a new
tube. Subsequently, 500 μL of buffer‐saturated phenol and
100 μL of DNA extraction buffer were added to the
suspension and the mixture vortexed vigorously. After
centrifugation at 14,000 rpm for 5min, 400 μL of super-
natant was collected into a new tube. Bacterial DNA was
then obtained by isopropanol precipitation. Bacterial DNA
was pelleted by centrifugation at 14,000 rpm for 5min and
washed with 70% ethanol. Finally, DNA was suspended in
100 μL of Tris‐EDTA buffer.
2.4 | Real‐time qPCR
Fecal DNA was used to analyze the bacterial groups
quantitatively. Quantitative real‐time PCR was performed
using a LightCycler 96 system (Roche Diagnostics, Man-
nheim, Germany). 16 S rRNA genes were amplified by
bacterial group‐specific primers. Primers were UniF340 5′‐
ACTCCTACGGGAGGCAGCAGT‐3′ and UniR514 5′‐ATT
ACCGCGGCTGCTGGC‐3′ for total bacteria, UniF338 5′‐A
CTCCTACGGGAGGCAGC‐3′ and C.cocR491 5′‐GCTTCTT
AGTCAGGTACCGTCAT‐3′ for Clostridiales, LabF362 5′‐
AGCAGTAGGGAATCTTCCA‐3′ and LabR677 5′‐CACCG
CTACACATGGAG‐3′ for Lactobacillaceae, BactF285 5′‐GG
TTCTGAGAGGAAGGTCCC‐3′ and UniR338 5′‐GCTGCC
TCCCGTAGGAGT‐3′ for Bacteroidales, and Uni515F 5′‐GT
GCCAGCAGCCGCGGTAA‐3′ and Ent826R 5′‐GCCTCA
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AGGGCACAACCTCCAAG‐3′ for Enterobacteriaceae.19 All
reactions were performed using a KAPA SYBR Fast qPCR
kit (Kapa Biosystems, Wilmington, MA, USA).
2.5 | 16 S rRNA gene amplicon
sequencing
Extracted fecal bacterial DNA was used to analyze the gut
microbiota composition on the basis of 16 S rRNA genes. 16 S
rRNA gene amplicon sequencing was performed as per the
Illumina 16 S Metagenomic Sequencing Library Preparation
protocol with modifications. Briefly, the corresponding
sequences were amplified using primers specific for the V3‐
V4 region of the 16 S rRNA genes. For the PCR reaction,
KAPA HiFi DNA polymerase (Kapa Biosystems) was used
and the PCR product purified using AMPure XP Beads
(Beckman Coulter, Brea, CA, USA). A second PCR was
performed using the purified PCR product as a template and
a Nextera DNA Index kit (Illumina, San Diego, CA, USA).
After purifying the second PCR products, the DNA
concentration was measured using a Qubit 4 fluorometer
(Thermo Fischer Scientific, Waltham, MA, USA) according
to the manufacturer's instructions. Combined samples at a
concentration of 10 pM were mixed with a PhiX Control kit
v3 (Illumina) and loaded onto a MiSeq Reagent Kit v2 500
cycle cartridge (Illumina) and the MiSeq sequencing plat-
form (Illumina). The 250‐bp paired‐end reads were merged
using PANDAseq (ver. 2.8) with the default parameters set to
other than “−l 400”.20 The merged sequences were analyzed
by the pick_open_reference_otus.py workflow of QIIME
(ver. 1.9.1) using the default parameters.21 The samples’
alpha‐ and beta‐diversities were calculated using the
core_diversity_analyses.py workflow of QIIME.
2.6 | C. albicans injection and detection
C. albicans (IFM 60662, ATCC 18804) obtained from the
Medical Mycology Research Center of Chiba University's
culture collection were routinely cultivated in potato
dextrose broth at 37°C before oral administration. A total
of 5 × 107C. albicans were orally administered to mice
receiving or not receiving antibiotics. Feces were collected
at the indicated time points, diluted and plated on PDA
containing chloramphenicol (0.05 g/L; Nacalai Tesque),
penicillin (0.6 g/L) and streptomycin (0.167 g/L). Systemic
tissues (spleen, kidney, and liver) were isolated from
ampicillin‐treated mice, homogenized using a TissueRuptor
(Qiagen, Hilden, Germany), and plated on PDA. Colonies
were counted after incubation for 2 d. Feces were collected
7 d after C. albicans injection to detect fungal DNA in
the feces. Primer sets specific for ITS rDNA sequences, ITS1
5′‐CTTGGTCATTTAGAGGAAGTAA‐3′ and ITS2 5′‐GC
TGCGTTCTTCATCGATGC‐3′, were used.10 ITS sequences
were amplified using EmeraldAmp PCR Master Mix
(TaKaRa, Shiga, Japan).
2.7 | FMT and antifungal drug
treatment
Mice treated with ampicillin were orally administered C.
albicans. After C. albicans colonization of the feces of these
mice had been confirmed by plating fecal diluents on PDA
containing chloramphenicol, penicillin, and streptomycin,
the mice were treated with fluconazole (0.5 g/L; LKT
Laboratories, St Paul, MN, USA), 5‐fluorocytosine (2 g/L;
TCI Chemicals, Tokyo, Japan), and amphotericin B (0.1 g/L;
Nacalai Tesque) mixed with drinking water containing
ampicillin.22,23 For the FMT, sterile water was substituted
for drinking water containing ampicillin 1 d before the FMT.
Donor feces were obtained from SPF C57BL/6 mice and
subjected to FMT. After homogenizing one or two fecal
pellets from donor mice in 1mL of water, the supernatants
were orally administered to a recipient mouse colonized
with C. albicans. For the control mice without FMT
treatment, sterile water was substituted for drinking water
containing ampicillin 1 d at the same time as FMT mice.
Feces were then collected from these recipient mice at the
indicated time points and the C. albicans counted.
2.8 | Statistical analysis
Statistical analyses were conducted using Microsoft Excel
and the GraphPad Prism software (San Diego, CA, USA).
Results were compared using two‐tailed Student's t‐tests
and Fisher's exact test. Data were plotted as means ± SD.
3 | RESULTS
3.1 | Experimental mice were resistant
to C. albicans colonization of the gut
Based on a previous report demonstrating that commensal
fungi endogenously colonize experimental mouse guts,10
we first used culture‐ and DNA‐based approaches to
investigate whether test mice had commensal fungi in their
GI tracts. In contrast to the previous report, we did not
detect fungi in the feces of experimental mice maintained
at our facility (Figure 1A,B). Therefore, we attempted to
establish colonization by C. albicans, a commensal and
pathogenic fungus, by administration this organism orally
to fungus‐free, wild‐type C57BL/6 mice. We detected
C. albicans in the feces immediately after oral administra-
tion; however, the number of fungi decreased gradually,
C. albicans eventually becoming undetectable in these mice
(Figure 1C). After failing to detect C. albicans in the feces,
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we examined luminal contents of various parts of the GI
tract (e.g., stomach, small intestine, cecum, and colon) and
did not detect C. albicans in these contents (Fig. 1D),
indicating that this organism had been completely cleared
from the GI tract. We also established that BALB/c mice
are resistant to C. albicans colonization of the GI tract (data
not shown). These data indicate that wild‐type mice are
resistant to C. albicans colonization of the GI tract.
3.2 | β‐lactam antibiotic treatment
enables C. albicans to colonize the gut
We next examined why wild‐type C57BL/6 mice are
resistant to C. albicans colonization of the gut. Given
that several environmental factors in murine guts can
affect Candida colonization, we hypothesized that
commensal microbes in the murine GI tract may
protect against Candida colonization. To determine
whether commensal microbes impacted C. albicans
colonization, we treated SPF mice with multiple
antibiotics. After antibiotic treatment, we collected
feces from these mice and plated them on PDA for
detection of C. albicans. We detected significant
numbers of C. albicans colonies in the feces of mice
treated with ampicillin or penicillin, both of which are
β‐lactam antibiotics (Figure 2A). Conversely, mice
treated with other antibiotics (vancomycin, metroni-
dazole, neomycin, colistin, streptomycin and gentamy-
cin) had almost the same number of C. albicans in their
feces as did the wild‐type mice (Figure 2A). We next
addressed whether C. albicans was detectable in the
luminal contents of the GI tracts of ampicillin‐treated
mice and found significant and comparable numbers of
C. albicans in the luminal contents from the stomach to
the colon of ampicillin‐treated mice, indicating that
C. albicans had successfully colonized the GI tracts of
these mice (Figure 2B). In the ampicillin‐treated mice,
these C. albicans levels were maintained for at least
3 months after administration (data not shown),
indicating that C. albicans had indeed colonized their
FIGURE 1 Experimental mice are resistant to C. albicans colonization of the GI tract. A, Culture‐based quantification of fungi of feces
isolated from wild‐type C57BL/6 mice and mice injected with C. albicans (n=4). Feces were collected 0 and 7 d after orally injecting C. albicans.
B, Fungus‐specific DNA was detected in feces isolated from mice injected with C. albicans but not in untreated C57BL/6 mice. CA, C. albicans;M,
marker; WT, wild‐type. C, C. albicans numbers in feces isolated from C57BL/6 mice injected with C. albicans were counted at the indicated time
points (n=10). Error bars, SD. D, C. albicans numbers of GI contents of mice 45 days after oral administration of C. albicans (n=3). ND, not
detected; SI, small intestine. Data from two to three independent experiments
158 | MATSUO ET AL.
GI tracts. We also found that C. albicans colonized the
GI tracts of ampicillin‐treated BALB/c mice as they did
the C57BL/6 mice (Figure 2C,D).
3.3 | Ampicillin treatment changes the
commensal microbiota composition in
mice
We next examined the bacterial compositions of ampicillin‐
treated and ‐untreated mouse microbiota. We isolated feces
from these mice and analyzed their bacterial compositions
based on 16 S rRNA gene amplicon sequencing. Gut
microbiota compositions and bacterial diversity changed
after ampicillin treatment (Figure 3A,B,C; Supplementary
Figure 1, 2; and Supplementary Table 1). We also examined
the bacterial compositions of the microbiota of other
antibiotic‐treated mice (Supplementary Figures 3, 4, 5; and
Supplementary Table 1). Each antibiotic induced specific
dysbiosis of fecal microbiota. We further investigated the
quantity of major bacterial genera in the feces of ampicillin‐
treated mice by qPCR. Quantitative analysis showed that
there were very much fewer Lactobacillaceae, Bacteroidales,
Clostridiales and Enterobacteriaceae in the ampicillin‐treated
mice (Figure 3D).
3.4 | Numbers of ccommensal bacteria
and C. albicans in the gut are inversely
correlated
In addition to specific bacterial groups, there were
dramatically fewer total commensal bacteria in the
ampicillin‐treated mice (Figure 4A), indicating that ampi-
cillin treatment induces dysbiosis in murine GI tracts. We
next investigated the quantitative kinetics of commensal
bacteria and C. albicans in the gut after ampicillin
treatment. A single oral administration of ampicillin
drastically reduced commensal bacterial numbers; however,
this effect was transient. Luminal bacterial numbers
recovered within 4 d of injecting ampicillin (Figure 4B).
To examine the relationship between C. albicans numbers
and commensal bacteria, we orally injected ampicillin into
mice and then administered C. albicans. C. albicans
numbers increased greatly immediately after these injec-
tions and were maintained for 4 d. Numbers of C. albicans
subsequently decreased to colonization levels comparable
to those of the ampicillin‐untreated mice by 7 d after
C. albicans injection (Figure 4C). These data suggest that
commensal bacterial colonization is inversely correlated
with C. albicans in the GI tract and that commensal bacteria
likely inhibit C. albicans colonization.
FIGURE 2 C. albicans colonizes ampicillin‐ and penicillin‐treated mice (A) C57BL/6 mice were treated with or not treated with the indicated
antibiotics. C. albicans in feces were counted 28 days after oral injection (n= 5). Amp, ampicillin; Col, colistin; Gen, gentamycin; Met,
metronidazole; Neo, neomycin; Pen, penicillin; Str, streptomycin; Vnc, vancomycin; WT: wild‐type. B, C. albicans numbers of GI contents of
C57BL/6 mice treated with ampicillin (n=5). C, C. albicans numbers of feces were counted 28 d after oral injection into BALB/c mice treated with
or without ampicillin (n=6). ND: not detected. D, C. albicans numbers in GI contents from ampicillin‐treated BALB/c mice (n= 6). SI: small
intestine. Error bars, SD. ***P<0.001, **P< 0.01 according to Student's t‐test. Data are representative of two independent experiments
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3.5 | FMT prevents C. albicans
colonization of murine GI tracts
We next investigated whether commensal bacteria have
therapeutic potential against C. albicans colonization of the
GI tract. Because FMT is a commensal, bacteria‐based,
therapeutic approach to treating pathogenic bacterial infec-
tions in the gut,8 we attempted FMT in C. albicans‐colonized
mice. After the FMT, C. albicans numbers in the feces were
drastically and immediately reduced compared with mice
that had not undergone FMT (Figure 4D). We found that
total numbers of commensal bacteria were restored 4 d after
FMT (Figure 4E). To compare the effects of FMT and
conventional antifungal drugs against C. albicans coloniza-
tion of the GI tract, we treated C. albicans‐colonized mice
with the antifungal reagents, fluconazole, 5‐fluorocytosine
and amphotericin B. Amphotericin B depleted C. albicans in
the gut, whereas fluconazole and 5‐fluorocytosine did not
(Figure 4F), indicating that FMT prevents C. albicans from
colonizing the murine GI tract.
4 | DISCUSSION
In this study, we showed that murine GI microbiota contain
potential therapeutic targets for C. albicans colonization of
the GI tract. Wild‐type experimental mice were resistant to
C. albicans colonization in the GI tract, whereas C. albicans
successfully colonized the GI tracts of mice treated with
antibiotics such as ampicillin, inducing dysbiosis in the gut
microbiota. FMT prevented C. albicans from colonizing the
GI tract. These data highlight that murine commensal
bacteria function as barriers and play roles in protecting the
host from C. albicans colonization.
The mechanism by which commensal bacteria inhibit
C. albicans colonization remains unclear. Several studies
have shown that the protective effects of commensal
bacteria against pathogenic bacteria are mediated by
differentiation and activation of host innate and acquired
immune cells in the gut.18,24 Commensal bacteria, espe-
cially SFB, induce Th17 cells, which protect against
Candida infection by producing IL‐17A and subsequently
activating neutrophils.25 However, SFB and Th17 cells are
unlikely to affect C. albicans colonization of the gut,
because vancomycin treatment—which effectively elimi-
nates SFB and Th17 cells—reportedly prevents C. albicans
colonization of the gut24,26 (Figure 2A). Further studies are
necessary to determine whether a commensal bacterial‐
immune cell‐axis affects C. albicans colonization of the gut.
Another possible mechanism is that commensal bacteria
directly protect against C. albicans colonization of the GI
FIGURE 3 Dysbiosis was induced in ampicillin‐treated mice (A), (B), (C) Based on 16 S rRNA genes in feces from ampicillin‐treated
and ‐untreated mice. A, PCoA Plots of unweighted UniFrac distances. B, alpha refraction curve. C, ratios of bacterial phyla are
represented. D, Quantitative real‐time qPCR analysis of bacterial groups in feces isolated from mice treated or not treated with ampicillin
(n= 5). Error bars, SD. **P< 0.01 according to Student's t‐test. Data are representative of three independent experiments
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tract. Commensal bacteria may compete with C. albicans for
oxygen, pH and nutrients in this environmental niche.
Commensal bacteria produce various metabolites in the gut
lumen that may impact C. albicans colonization and
proliferation.
Although we investigated the microbiota in mice treated
with multiple antibiotics in this study, the specific bacterial
species that protect against colonization by C. albicans of the
GI tract are still unknown. C. albicans colonized the GI tracts
of mice treated with ampicillin and penicillin, both of which
dramatically reduced the number of total and specific
commensal bacteria (Figures 3D, 4A; data not shown). In
contrast, mice treated with other antibiotics that induce
dysbiosis (Supplementary Figures 3, 4, 5; and Supplementary
Table 1) were resistant to C. albicans colonization (Figure
2A), suggesting that several bacterial species may be involved
in protection against C. albicans colonization. We also found
by 16 s rRNA sequence analysis that vancomycin‐treated
mice predominantly harbor Lactobacillaceae (Supplementary
Figure 6; and Supplementary Table 1). Taken together with
the data that vancomycin‐treated mice are resistant to C.
albicans colonization, these data suggest that Lactobacillaceae
are one of the types of commensal bacteria responsible for
protection against C. albicans colonization in vivo. Indeed, a
previous study showed that Lactobacillus inhibits expression
of virulence factors of C. albicans in vitro.27 The specific
kinds of bacteria and detailed mechanism of Lactobacillus
protecting against C. albicans colonization of the GI tract
require investigation in future studies.
Because commensal bacteria affect C. albicans coloniza-
tion, the intestinal environment that influences the com-
mensal population may be critical for C. albicans
colonization of the GI tract. The factors that determine C.
albicans colonization, including environmental factors such
as food, water and bedding, and how these factors affect the
commensal bacterial composition and subsequent C. albicans
colonization of the GI tract remain unclear. Indeed, several
fungi, including Saccharomyces, Trichosporon and Candida
species, have been found to colonize endogenously, even in
SPF mice bred in another experimental facility.10 Conversely,
other groups have reported fungus‐free SPF mice.28
C. albicans colonization of the GI tract is considered a
trigger for invasive candidiasis.11 However, C. albicans were
minimally detectable in the systemic tissues, even in
ampicillin‐treated C. albicans‐colonized mice (Supplemen-
tary Figure 7 and Supplementary Table 2). Conversely, many
C. albicans were detected in the systemic tissues after i.v.
injection, indicating that C. albicans can reach systemic
FIGURE 4 FMT prevents C. albicans from entering the GI tract (A) Real‐time qPCR analysis of total bacteria in feces isolated from mice
treated or not treated with ampicillin (n= 5). B, Relative numbers of total fecal bacteria were analyzed using real‐time qPCR before and after
injecting ampicillin (n= 5). C, C. albicans counts of feces from ampicillin‐treated or ‐untreated mice (n= 5). D, C. albicans‐colonized mice
received water or FMT after cessation of ampicillin treatment. C. albicans counts of feces from mice at 0, 7 and 28 d after administration
(n= 3). E, Relative numbers of total fecal bacteria from mice transferred with fecal microbiota were examined at the indicated time points
(n= 3). F, C. albicans‐colonized mice treated or not treated with antifungal drugs. C. albicans counts of feces from mice at 0, 7 and 28 d after
administration (n = 3). Amph, amphotericin B;Cont, control; Fluc, fluconazole; 5‐FC, 5‐fluorocytosine; ND, not detected. Error bars, SD.
*P< 0.05, **P< 0.01 according to Student's t‐test. Data are representative of two independent experiments
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compartments via the bloodstream (Supplementary Figure 3
and Supplementary Table 2). These data suggest that the
host's surface barrier system, particularly the gut epithelial
cells and immune system, may prevent C. albicans from
infiltrating blood vessels and that commensal bacteria
may be important to the surface barriers preventing C.
albicans infections. In addition to life‐threatening systemic
fungal infections in immunocompromised patients, fungal
colonization of the GI tract exacerbates allergic airway
inflammation.22 Thus, controlling fungal colonization may
be an effective strategy for regulating both infections and
inflammation and allergies. Targeted modification of com-
mensal bacteria may provide novel approaches for control-
ling these diseases.
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